Gicht und andere Kristallarthropathien

Schlüsselwörter

Gicht - Pseudogicht - Hyperurikämie - Febuxostat - Pegloticase

Keywords

gout - pseudogout - hyperuricemia - febuxostat - pegloticase

• Literatur

• 1 Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheum 2011; 38: 1957-1959
• 2 Dalbeth N, McQueen FM et al. Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheum 2011; 38: 1458-1461
• 3 Goldfarb DS, McDonald PA, Hunt B et al. Febuxostat in gout: Serum urate response in uric acid overproducers and underexcretors. J Rheumatol 2011; 38: 1585-1589
• 4 Howard RG, Pillinger MH, Gyftopoulos S et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res 2011; 63: 1456-1462
• 5 Manger B, Lell M, Wacker J et al. Detection of periarticular urate deposits with dual energy CT in patients with acute gouty arthritis. Ann Rheum Dis 2012; 71: 470-472
• 6 Roddy E. Revisiting the pathogenesis of podagra: why does gout target the foot?. J Foot Ankle Res 2011; 4: 13
• 7 Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009; 68: 1265-1270
• 8 Smith EUR, Diaz-Torne C, Perez-Ruiz F et al. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol 2010; 24: 811-827
• 9 Soriano LC, Rothenbacher D et al. Contemporary epidemiology of gout in the UK general population. Arthritis Res Ther 2011; 13: R39
• 10 Stocker SL, Graham GG et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011; 38: 904-910
• 11 Sundy JS, Baraf HSB, Yood RA et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment. JAMA 2011; 306: 711-720
• 12 Zhang W, Doherty M, Bardin T et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70: 563-570
• 13 Zhang W, Doherty M, Pascual E et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011; 70: 571-575
• 14 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population. Arthritis Rheum 2011; 63: 3163-3141